Harbor Capital Advisors Inc. Has $3.11 Million Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Harbor Capital Advisors Inc. boosted its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 73.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 168,506 shares of the biotechnology company's stock after acquiring an additional 71,372 shares during the quarter. Harbor Capital Advisors Inc. owned 0.19% of Rocket Pharmaceuticals worth $3,112,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently made changes to their positions in RCKT. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Rocket Pharmaceuticals by 75.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 301,832 shares of the biotechnology company's stock valued at $8,131,000 after acquiring an additional 129,358 shares during the period. Nordea Investment Management AB raised its position in shares of Rocket Pharmaceuticals by 0.8% in the 1st quarter. Nordea Investment Management AB now owns 154,070 shares of the biotechnology company's stock worth $4,140,000 after acquiring an additional 1,209 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Rocket Pharmaceuticals by 3.5% during the 1st quarter. Jennison Associates LLC now owns 26,783 shares of the biotechnology company's stock valued at $722,000 after purchasing an additional 903 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Rocket Pharmaceuticals by 4.1% during the 1st quarter. Russell Investments Group Ltd. now owns 675,769 shares of the biotechnology company's stock valued at $18,205,000 after purchasing an additional 26,823 shares during the last quarter. Finally, ProShare Advisors LLC raised its position in Rocket Pharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 17,614 shares of the biotechnology company's stock worth $475,000 after buying an additional 1,468 shares during the last quarter. Institutional investors own 98.39% of the company's stock.

Rocket Pharmaceuticals Trading Up 2.2 %

RCKT stock traded up $0.37 during midday trading on Tuesday, reaching $17.19. 968,277 shares of the company's stock traded hands, compared to its average volume of 777,673. The business has a 50-day moving average price of $18.15 and a two-hundred day moving average price of $20.57. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.79 and a quick ratio of 7.79. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $15.98 and a fifty-two week high of $32.53. The company has a market capitalization of $1.56 billion, a P/E ratio of -6.00 and a beta of 1.09.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last released its earnings results on Monday, August 5th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.02). During the same period in the prior year, the company earned ($0.82) EPS. Equities research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on RCKT. Cantor Fitzgerald restated an "overweight" rating and set a $65.00 price target on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 6th. JPMorgan Chase & Co. upped their price objective on shares of Rocket Pharmaceuticals from $50.00 to $54.00 and gave the company an "overweight" rating in a research note on Tuesday, August 6th. Needham & Company LLC reissued a "buy" rating and issued a $52.00 price objective on shares of Rocket Pharmaceuticals in a report on Tuesday, September 17th. Scotiabank started coverage on Rocket Pharmaceuticals in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $50.00 target price for the company. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $38.00 price target on shares of Rocket Pharmaceuticals in a research note on Monday, September 30th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $51.75.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.